294 related articles for article (PubMed ID: 20487546)
1. Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia.
Moussay E; Palissot V; Vallar L; Poirel HA; Wenner T; El Khoury V; Aouali N; Van Moer K; Leners B; Bernardin F; Muller A; Cornillet-Lefebvre P; Delmer A; Duhem C; Ries F; van Dyck E; Berchem G
Mol Cancer; 2010 May; 9():115. PubMed ID: 20487546
[TBL] [Abstract][Full Text] [Related]
2. MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia.
Ferracin M; Zagatti B; Rizzotto L; Cavazzini F; Veronese A; Ciccone M; Saccenti E; Lupini L; Grilli A; De Angeli C; Negrini M; Cuneo A
Mol Cancer; 2010 May; 9():123. PubMed ID: 20504344
[TBL] [Abstract][Full Text] [Related]
3. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.
Rossi D; Fangazio M; Rasi S; Vaisitti T; Monti S; Cresta S; Chiaretti S; Del Giudice I; Fabbri G; Bruscaggin A; Spina V; Deambrogi C; Marinelli M; Famà R; Greco M; Daniele G; Forconi F; Gattei V; Bertoni F; Deaglio S; Pasqualucci L; Guarini A; Dalla-Favera R; Foà R; Gaidano G
Blood; 2012 Mar; 119(12):2854-62. PubMed ID: 22308293
[TBL] [Abstract][Full Text] [Related]
4. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response.
Rosenwald A; Chuang EY; Davis RE; Wiestner A; Alizadeh AA; Arthur DC; Mitchell JB; Marti GE; Fowler DH; Wilson WH; Staudt LM
Blood; 2004 Sep; 104(5):1428-34. PubMed ID: 15138159
[TBL] [Abstract][Full Text] [Related]
5. miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes.
Zhu DX; Zhu W; Fang C; Fan L; Zou ZJ; Wang YH; Liu P; Hong M; Miao KR; Liu P; Xu W; Li JY
Carcinogenesis; 2012 Jul; 33(7):1294-301. PubMed ID: 22610076
[TBL] [Abstract][Full Text] [Related]
6. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
[TBL] [Abstract][Full Text] [Related]
7. DNA polymerase ν gene expression influences fludarabine resistance in chronic lymphocytic leukemia independently of p53 status.
Grgurevic S; Montilla-Perez P; Bradbury A; Gilhodes J; Queille S; Pelofy S; Bancaud A; Filleron T; Ysebaert L; Récher C; Laurent G; Fournié JJ; Cazaux C; Quillet-Mary A; Hoffmann JS
Haematologica; 2018 Jun; 103(6):1038-1046. PubMed ID: 29567785
[TBL] [Abstract][Full Text] [Related]
8. Impaired up-regulation of polo-like kinase 2 in B-cell chronic lymphocytic leukaemia lymphocytes resistant to fludarabine and 2-chlorodeoxyadenosine: a potential marker of defective damage response.
de Viron E; Knoops L; Connerotte T; Smal C; Michaux L; Saussoy P; Vannuffel P; Beert E; Vekemans MC; Hermans C; Bontemps F; Van Den Neste E
Br J Haematol; 2009 Dec; 147(5):641-52. PubMed ID: 19764992
[TBL] [Abstract][Full Text] [Related]
9. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.
Rossi D; Bruscaggin A; Spina V; Rasi S; Khiabanian H; Messina M; Fangazio M; Vaisitti T; Monti S; Chiaretti S; Guarini A; Del Giudice I; Cerri M; Cresta S; Deambrogi C; Gargiulo E; Gattei V; Forconi F; Bertoni F; Deaglio S; Rabadan R; Pasqualucci L; Foà R; Dalla-Favera R; Gaidano G
Blood; 2011 Dec; 118(26):6904-8. PubMed ID: 22039264
[TBL] [Abstract][Full Text] [Related]
10. Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia.
Pandzic T; Larsson J; He L; Kundu S; Ban K; Akhtar-Ali M; Hellström AR; Schuh A; Clifford R; Blakemore SJ; Strefford JC; Baumann T; Lopez-Guillermo A; Campo E; Ljungström V; Mansouri L; Rosenquist R; Sjöblom T; Hellström M
Clin Cancer Res; 2016 Dec; 22(24):6217-6227. PubMed ID: 26957556
[TBL] [Abstract][Full Text] [Related]
11. Constitutively Photomorphogenic 1 Reduces the Sensitivity of Chronic Lymphocytic Leukemia Cells to Fludarabine Through Promotion of Ubiquitin-Mediated P53 Degradation.
Fu C; Shi X; Gong Y; Wan Y; Sun Z; Shi H; Wang Z; Marinaccio C; Crispino JD; Xu K
Cell Physiol Biochem; 2018; 50(6):2314-2328. PubMed ID: 30423551
[TBL] [Abstract][Full Text] [Related]
12. p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV.
Valgañón M; Giraldo P; Agirre X; Larráyoz MJ; Rubio-Martinez A; Rubio-Felix D; Calasanz MJ; Odero MD
Br J Haematol; 2005 Apr; 129(1):53-9. PubMed ID: 15801955
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations.
Mackey JR; Galmarini CM; Graham KA; Joy AA; Delmer A; Dabbagh L; Glubrecht D; Jewell LD; Lai R; Lang T; Hanson J; Young JD; Merle-Béral H; Binet JL; Cass CE; Dumontet C
Blood; 2005 Jan; 105(2):767-74. PubMed ID: 15454483
[TBL] [Abstract][Full Text] [Related]
14. Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine.
Cejkova S; Rocnova L; Potesil D; Smardova J; Novakova V; Chumchalova J; Zezulkova D; Borsky M; Doubek M; Brychtova Y; Pospisilova S; Klabusay M; Mayer J; Trbusek M
Eur J Haematol; 2009 Feb; 82(2):133-42. PubMed ID: 19018867
[TBL] [Abstract][Full Text] [Related]
15. DNA-PK, ATM and MDR proteins inhibitors in overcoming fludarabine resistance in CLL cells.
Svirnovski AI; Serhiyenka TF; Kustanovich AM; Khlebko PV; Fedosenko VV; Taras IB; Bakun AV
Exp Oncol; 2010 Dec; 32(4):258-62. PubMed ID: 21270755
[TBL] [Abstract][Full Text] [Related]
16. Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs.
Silber R; Degar B; Costin D; Newcomb EW; Mani M; Rosenberg CR; Morse L; Drygas JC; Canellakis ZN; Potmesil M
Blood; 1994 Nov; 84(10):3440-6. PubMed ID: 7949099
[TBL] [Abstract][Full Text] [Related]
17. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
[TBL] [Abstract][Full Text] [Related]
18. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage.
Malcikova J; Smardova J; Rocnova L; Tichy B; Kuglik P; Vranova V; Cejkova S; Svitakova M; Skuhrova Francova H; Brychtova Y; Doubek M; Brejcha M; Klabusay M; Mayer J; Pospisilova S; Trbusek M
Blood; 2009 Dec; 114(26):5307-14. PubMed ID: 19850740
[TBL] [Abstract][Full Text] [Related]
19. [Research advance on fludarabine resistance mechanisms in chronic lymphocytic leukemia cells].
Yao L; Xu W; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):821-4. PubMed ID: 20561458
[TBL] [Abstract][Full Text] [Related]
20. The BH3-only protein Puma plays an essential role in p53-mediated apoptosis of chronic lymphocytic leukemia cells.
Zhu HJ; Liu L; Fan L; Zhang LN; Fang C; Zou ZJ; Li JY; Xu W
Leuk Lymphoma; 2013 Dec; 54(12):2712-9. PubMed ID: 23517560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
